|
Inpatient and Outpatient Orderable
Comprehensive Cancer Genetic Panel
Synonyms
|
- COMPREHENSIVE CANCER PANEL
- LAB11067
|
Cerner Name
|
Comprehensive Cancer Panel
|
Clinical Info
|
This test is appropriate when the patient's differential diagnosis includes various hereditary cancer syndromes. The Comprehensive Cancer panel offers increased clinical sensitivity compared to testing for a few genes at a time since it tests for multiple syndromes at once across multiple cancer types. Molecular diagnosis may help in determining treatment and management, as well as identification of at risk family members.
|
Specimen Sources
|
Blood, Arterial
Blood, Capillary
Blood, Central Line
Blood, Venous
|
Specimen Types
|
Blood
|
Container
|
Lavender top tube or Buccal (Oral Cheek Swab)
|
Collection Instructions
|
Container/Tube: Lavender top tube Specimen: 2 - 5 mL whole blood Note: Clinical Information required for complete interpretation Alternate sample type: DNA: Extract and submit DNA 50 ng/mL (total volume 400 mL) in sterile container. Ship DNA in sealed and protective packaging at ambient temperature, using a cool pack in hot weather. Labeling: Name of person or identifier, DNA concentration and volume MUST be provided on the specimen tube.
|
Specimen Volume
|
2 - 5 mL whole blood
|
Transport Instructions
|
Room Temperature
|
Specimen Stability
|
7 Days RefrigeratedBlood samples older than 7 days can still be shipped, they will be tested if the yield and quality of DNA permit.
|
Methodology
|
Deletion/Duplication Analysis Next-Gen Sequencing
|
Days Performed
|
TAT: 2 Weeks This test is appropriate when the patient's differential diagnosis includes various hereditary cancer syndromes. For example, if the family history consists of multiple cases of ovarian cancer, this may be associated with a breast/ovarian cancer syndrome such as BRCA1 or BRCA2 or Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM). This test may be appropriate when the patient family history includes a number of cancer cases, but they are of several different types, the pattern does not seem to fit any one hereditary cancer syndrome in particular, or if some genetic testing has already been ordered due to a family history suggestive of a hereditary cancer predisposition but all results have been negative. The Comprehensive Cancer panel offers increased clinical sensitivity compared to testing for a few genes at a time since it tests for multiple syndromes at once across multiple cancer types. Molecular diagnosis may help in determining treatment and management, as well as identification of at risk family members.
|
Performing Laboratory
|
GeneDx (B275)
|
CPT
|
81432
|
PDM
|
1659841
|
Only Orderable at Locations:
|
Orderable Everywhere
|
Results
|
Component Name |
Base Name |
Common Name |
External Name |
COMPREHENSIVE CANCER PANEL |
COMONCPAN |
COMPREHENSIVE CANCER PANEL |
Comprehensive Cancer Panel |
|
Result Interpretation
See Report Includes Genes: APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, CTNNA1, EPCAM, FANCC, FANCM, FH, FLCN, HOXB13, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTEN, RAD51C, RAD51D, RECQL, SCG5 (GREM1), SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL
|
Forms
|
|
LAB11067
|